|Assessment Status||Rapid Review Complete|
|Indication||As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.|
|Rapid review commissioned||06/12/2017|
|Rapid review completed||21/12/2017|
|Rapid review outcome||Full pharmacoeconomic assessment recommended at the submitted price.|
The HSE has approved reimbursement following confidential price negotiations – November 2018.